company background image
RGS

Regeneus ASX:RGS Stock Report

Last Price

AU$0.043

Market Cap

AU$13.2m

7D

0%

1Y

-41.9%

Updated

07 Dec, 2022

Data

Company Financials
RGS fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health1/6
Dividends0/6

RGS Stock Overview

Regeneus Ltd, a clinical stage regenerative medicine company, develops cell-based therapies for the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain, and dermatology diseases in Australia.

Regeneus Ltd Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Regeneus
Historical stock prices
Current Share PriceAU$0.043
52 Week HighAU$0.094
52 Week LowAU$0.038
Beta-0.11
1 Month Change7.50%
3 Month Change-8.51%
1 Year Change-41.89%
3 Year Change-48.19%
5 Year Change-69.29%
Change since IPO-84.07%

Recent News & Updates

Recent updates

Have Insiders Been Buying Regeneus Ltd (ASX:RGS) Shares?

Nov 30
Have Insiders Been Buying Regeneus Ltd (ASX:RGS) Shares?

Shareholder Returns

RGSAU BiotechsAU Market
7D0%-0.08%-1.8%
1Y-41.9%-5.0%-4.7%

Return vs Industry: RGS underperformed the Australian Biotechs industry which returned -4.1% over the past year.

Return vs Market: RGS underperformed the Australian Market which returned -4.1% over the past year.

Price Volatility

Is RGS's price volatile compared to industry and market?
RGS volatility
RGS Average Weekly Movement9.7%
Biotechs Industry Average Movement8.8%
Market Average Movement8.9%
10% most volatile stocks in AU Market15.8%
10% least volatile stocks in AU Market4.1%

Stable Share Price: RGS is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: RGS's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2007n/aKarolis Rosickashttps://regeneus.com.au

Regeneus Ltd, a clinical stage regenerative medicine company, develops cell-based therapies for the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain, and dermatology diseases in Australia. Its lead platform technology includes Progenza, a multi-synergistic therapy for the treatment of osteoarthritis and neuropathic pain. The company also develops Sygenus for the treatment of skin wound healing.

Regeneus Ltd Fundamentals Summary

How do Regeneus's earnings and revenue compare to its market cap?
RGS fundamental statistics
Market CapAU$13.18m
Earnings (TTM)-AU$4.31m
Revenue (TTM)AU$525.01k

25.1x

P/S Ratio

-3.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
RGS income statement (TTM)
RevenueAU$525.01k
Cost of RevenueAU$0
Gross ProfitAU$525.01k
Other ExpensesAU$4.83m
Earnings-AU$4.31m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.014
Gross Margin100.00%
Net Profit Margin-820.89%
Debt/Equity Ratio93.0%

How did RGS perform over the long term?

See historical performance and comparison